Nobel Laureate Develops Hantavirus Vaccine, WHO Reports Low Public Risk

A Nobel laureate involved in the COVID vaccine is developing a hantavirus vaccine, expected in ten months, while the WHO states the risk to the general public from the deadly hantavirus strain is very low due to its limited spread.